Back to resultsTreating Alzheimer's and Dementia With D-ribose
Primary Purpose
Alzheimers, Dementia
Status
Terminated
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
d-ribose
Sponsored by
About this trial
This is an interventional treatment trial for Alzheimers
Eligibility Criteria
Inclusion Criteria:
- A diagnosis of Alzheimer's and/or dementia with a Mini Mental Status Exam ( MMSE) score over 12 or being ambulatory and able to travel outside the home with assistance.
- Must have a caregiver living with them.
Exclusion Criteria:
- Overt and severe causes of secondary dementia such as metastatic brain cancers, or severe overt infectious encephalopathies or severe autoimmune illness.
- Also, severe life threatening illnesses which would make them unlikely to be alive after 6-12 months.
Sites / Locations
- PAN
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Treatment with d-ribose
Arm Description
Treatment with ribose 5 gm TID
Outcomes
Primary Outcome Measures
ADAS-ADL
Secondary Outcome Measures
Full Information
NCT ID
NCT02260141
First Posted
October 5, 2014
Last Updated
May 6, 2020
Sponsor
Practitioners Alliance Network
1. Study Identification
Unique Protocol Identification Number
NCT02260141
Brief Title
Treating Alzheimer's and Dementia With D-ribose
Study Type
Interventional
2. Study Status
Record Verification Date
October 2017
Overall Recruitment Status
Terminated
Why Stopped
unable to get adequate enrollment
Study Start Date
September 2014 (Actual)
Primary Completion Date
October 2017 (Actual)
Study Completion Date
October 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Practitioners Alliance Network
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
To study the effectiveness of d-ribose in treating Alzheimer's and Dementia
Detailed Description
Clinical experience and the pathophysiology of Alzheimer's, including neuronal insulin resistance, suggests that ribose improves clinical outcomes. This study will add ribose 5 gm 3 X day for 8 weeks to monitor outcomes in a pilot study.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Alzheimers, Dementia
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
Single arm pilot study using ribose for alzheimers
Masking
None (Open Label)
Allocation
N/A
Enrollment
3 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Treatment with d-ribose
Arm Type
Experimental
Arm Description
Treatment with ribose 5 gm TID
Intervention Type
Dietary Supplement
Intervention Name(s)
d-ribose
Intervention Description
giving ribose in those with a diagnosis of Alzheimer's and/or dementia
Primary Outcome Measure Information:
Title
ADAS-ADL
Time Frame
2 months
10. Eligibility
Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
A diagnosis of Alzheimer's and/or dementia with a Mini Mental Status Exam ( MMSE) score over 12 or being ambulatory and able to travel outside the home with assistance.
Must have a caregiver living with them.
Exclusion Criteria:
Overt and severe causes of secondary dementia such as metastatic brain cancers, or severe overt infectious encephalopathies or severe autoimmune illness.
Also, severe life threatening illnesses which would make them unlikely to be alive after 6-12 months.
Facility Information:
Facility Name
PAN
City
Kailua
State/Province
Hawaii
ZIP/Postal Code
96740
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Treating Alzheimer's and Dementia With D-ribose
We'll reach out to this number within 24 hrs